The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients

Amandeep Mann, Sharon L. Miksys, Andrea Gaedigk, Stephen J. Kish, Deborah C. Mash, Rachel F. Tyndale

Research output: Contribution to journalArticlepeer-review

54 Scopus citations


Cytochrome P450 2D6 (CYP2D6) is a drug-metabolizing enzyme expressed in the brain that also metabolizes endogenous neural compounds (e.g., catecholamines) and inactivates neurotoxins (e.g., 1-methyl-4-thenyl-1,2,3,6-tetrahydropyridine; MPTP). Genetically poor CYP2D6 metabolizers are at higher risk for developing Parkinson's disease (PD), a risk that increases with exposure to pesticides. As age is a risk factor for PD we measured the ontogenic expression of CYP2D6 in human brain, and compared brain CYP2D6 levels in PD cases with age-matched controls. CYP2D6 increased from fetal to 80 years of age (n = 76), exhibiting 3 distinct phases of change. Compared with PD controls, PD cases had approximately 40% lower CYP2D6 levels in the frontal cortex, cerebellum, and the hippocampus, even when controlling for CYP2D6 genotype. In contrast, CYP2D6 levels in cases were similar to controls in PD-affected brain areas, the substantia nigra, and caudate, consistent with higher astrocytic and cellular CYP2D6 staining observed in PD cases. In summary, the lower CYP2D6 levels in PD cases may have reduced their ability to inactivate PD-causing neurotoxins contributing to their disease risk.

Original languageEnglish (US)
Pages (from-to)2160-2171
Number of pages12
JournalNeurobiology of aging
Issue number9
StatePublished - Sep 2012


  • Aging
  • CNS drugs
  • CYP2D6
  • Human brain
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Aging
  • Developmental Biology
  • Geriatrics and Gerontology


Dive into the research topics of 'The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients'. Together they form a unique fingerprint.

Cite this